How effective is the 2025-2026 influenza H3N2 vaccine at preventing hospitalizations across age groups?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Early 2025–26 field estimates indicate the H3N2 component of this season’s vaccine is substantially protective against severe outcomes in children but only modestly protective in adults, with children and adolescents showing roughly 72–75% effectiveness against emergency-department attendance or hospital admission and adults showing about 30–40% effectiveness; older adults’ protection appears lower and more variable, and immunization remains recommended because it still lowers the risk of hospitalization [1] [2] [3].
1. What the early numbers say: strong protection in kids, modest in adults
England’s early vaccine-effectiveness analysis, conducted in a season dominated by H3N2 subclade K, found VE against influenza-associated emergency department attendances and hospital admissions of about 72–75% in children and adolescents (<18 years) and 32–39% in adults, figures repeated in contemporaneous reporting and preprint summaries [1] [2] [3].
2. Southern Hemisphere and prior season data give context to those estimates
Interim Southern Hemisphere 2025 data showed vaccines reduced SARI (severe acute respiratory infection) hospitalizations roughly by half overall, but subtype-specific VE against H3N2 hospitalizations was lower—around 37.2%—with higher VE observed among young children and lower VE among older adults, suggesting the English mid‑season findings are consistent with global signals [4].
3. Why the numbers differ by age: biology, prior immunity, and vaccine formulation
Younger people typically mount stronger responses to new vaccines and had higher VE in multiple datasets this season, while older adults both have weaker immune responses and show more variability in protection; randomized and observational studies have shown adjuvanted or high‑dose vaccines reduce respiratory and influenza‑related hospitalizations in older adults more than standard‑dose vaccines, a point public‑health bodies consider when recommending formulations [5].
4. The elephant in the lab: subclade K and antigenic mismatch concerns
Laboratory antigenic assays showed reduced reactivity of post‑infection ferret antisera raised to the Northern Hemisphere vaccine strains against the emergent H3N2 subclade K, raising theoretical concerns about reduced effectiveness; yet real‑world early VE against severe outcomes in children and many adults so far has remained within “typical” or expected ranges despite that antigenic drift [1] [2].
5. Limitations and uncertainty: early estimates, geography, and study design
These are early, observational estimates—some preliminary or preprint—and mostly reflect England and Southern Hemisphere surveillance; vaccine effectiveness can shift as more data accumulate, as circulation patterns change, and as different populations (for example, the U.S.) see different subtype mixes; past U.S. multistate data have at times shown weak or nonsignificant VE for H3N2 hospitalizations (a season where H3N2 VE crossed the null at 19%), underscoring variability by season and population [6] [1] [4].
6. Practical bottom line for public health impact
Translated into outcomes, a VE of roughly 72–75% in children means the vaccine is preventing a large share of pediatric hospital presentations this season, whereas VE in adults of ~30–40% still meaningfully reduces hospitalizations at the population level—particularly among those with risk factors—so vaccination remains a key tool even when antigenic drift is detected [1] [3] [4].
7. What to watch next: surveillance, hospital data, and vaccine mix
Ongoing surveillance for whether subclade K expands, updated VE estimates by age and by vaccine formulation, and hospitalization trends over the full season will determine whether early mid‑season estimates hold; public health agencies (CDC, WHO, national agencies) and peer‑reviewed analyses should be watched for updated, geographically diverse VE estimates and recommendations on high‑dose or adjuvanted options for older adults [2] [7] [5].